Edition:
United States

Vascular Biogenics Ltd (VBLT.OQ)

VBLT.OQ on NASDAQ Stock Exchange Global Market

6.15USD
20 Feb 2018
Change (% chg)

-- (--)
Prev Close
$6.15
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
56,952
52-wk High
$9.05
52-wk Low
$3.95

Latest Key Developments (Source: Significant Developments)

VBL Therapeutics Receives Milestone Payment From Nanocarrier Under Licensing Agreement For VB-111 In Japan
Thursday, 8 Feb 2018 07:00am EST 

Feb 8 (Reuters) - Vascular Biogenics Ltd ::VBL THERAPEUTICS RECEIVES MILESTONE PAYMENT FROM NANOCARRIER UNDER LICENSING AGREEMENT FOR VB-111 IN JAPAN.VBL THERAPEUTICS RECEIVES MILESTONE PAYMENT FROM NANOCARRIER UNDER LICENSING AGREEMENT FOR VB-111 IN JAPAN.‍AMOUNT OF RECENT MILESTONE PAYMENT WAS NOT DISCLOSED.​.  Full Article

Vascular Biogenics Says Top-Line Data From Globe Phase 3 Pivotal Trial Of VB-111 Expected In Q1 Of 2018
Wednesday, 27 Dec 2017 07:00am EST 

Dec 27 (Reuters) - Vascular Biogenics Ltd ::VASCULAR BIOGENICS - TOP-LINE DATA FROM GLOBE PHASE 3 PIVOTAL TRIAL OF VB-111 EXPECTED IN Q1 OF 2018.  Full Article

VBL therapeutics Q3 loss per share $0.24
Tuesday, 14 Nov 2017 07:00am EST 

Nov 14 (Reuters) - Vascular Biogenics Ltd :VBL Therapeutics announces third quarter 2017 financial results.Q3 loss per share $0.24.Q3 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S.Vascular Biogenics Ltd - ‍ remain on-track to initiate a phase 3 study of vb-111 in ovarian cancer by year-end 2017​.Vascular Biogenics Ltd - ‍ also planning an exploratory clinical study in combination with a checkpoint inhibitor in lung cancer in q1 of 2018​.Vascular Biogenics - ‍expect cash, cash equivalents, short-term bank deposits to enable funding operating expenses and capex requirements through 2019​.  Full Article

VBL Therapeutics and Nanocarrier signs agreement for VB-111 in Japan
Monday, 6 Nov 2017 07:00am EST 

Nov 6 (Reuters) - Nanocarrier Co Ltd <4571.T>:VBL Therapeutics and Nanocarrier Co Ltd sign exclusive agreement for VB-111 in Japan.Vascular Biogenics Ltd - ‍Nanocarrier receives exclusive rights to VB-111 in Japan, VBLT retains rights in rest of world​.Vascular - Pursuant to agreement, VBLT to supply nanocarrier with VB-111.Vascular - Nanocarrier will be responsible for all regulatory, other clinical activities necessary for commercialization of VB-111 in Japan.Vascular - VBLT receives up-front payment of $15 million & is entitled to receive greater than $100 million in development & commercial milestone payments​.Vascular Biogenics Ltd - ‍VBLT will also receive tiered royalties on net sales in high-teens​.Vascular Biogenics Ltd - ‍Other terms of agreement not disclosed​.  Full Article

Nanocarrier signs exclusive agreement with VBL Therapeutics for VB-111 in Japan
Sunday, 5 Nov 2017 09:40pm EST 

Nov 6 (Reuters) - NanoCarrier Co Ltd <4571.T>:Says co signs an exclusive license agreement with VBL Therapeutics, for the development, commercialization, and supply of ofranergene obadenovec ("VB-111") in Japan.Under terms of the agreement, VBL Therapeutics will supply the co with VB-111, and the co will be responsible for all regulatory and other clinical activities necessary for commercialization in Japan.Says VBL Therapeutics will receive up-front payment of $15 million, development and commercial milestone payments and tiered royalties on net sales from the co.  Full Article

VBL THERAPEUTICS OPENS NEW GENE THERAPY MANUFACTURING PLANT, HEADQUARTERS
Monday, 23 Oct 2017 08:05am EDT 

Oct 23 (Reuters) - Vascular Biogenics Ltd ::VBL THERAPEUTICS CELEBRATES OPENING OF ITS NEW GENE THERAPY MANUFACTURING PLANT AND COMPANY HEADQUARTERS.PLANT IN MODIIN, ISRAEL WILL BE COMMERCIAL FACILITY FOR PRODUCTION OF OFRANERGENE OBADENOVEC (VB-111), IF APPROVED​.‍VBL EXPECTS THAT CURRENT CASH WILL FUND COMPANY'S OPERATING EXPENSES AND CAPITAL EXPENDITURE REQUIREMENTS INTO 2019​.  Full Article

VBL Therapeutics says VB-111 given orphan drug designation in Europe
Friday, 20 Oct 2017 07:00am EDT 

Oct 20 (Reuters) - Vascular Biogenics Ltd :VBL Therapeutics announces orphan drug designation for VB-111 in Europe.VBL Therapeutics - ‍European Medicines Agency designated ofranergene obadenovec as an "orphan medicinal product" for treatment of ovarian cancer​.  Full Article

VBL Therapeutics announces positive outcome in third, final DSMC review of phase 3 globe trial investigating VB-111 in recurrent GBM
Monday, 2 Oct 2017 07:00am EDT 

Oct 2 (Reuters) - Vascular Biogenics Ltd ::VBL Therapeutics announces positive outcome in the third and final dsmc review of phase 3 globe trial investigating vb-111 in recurrent GBM.Vascular Biogenics Ltd - ‍dsmc confirmed that no additional follow up will be necessary.Vascular Biogenics Ltd - ‍dsmc unanimously recommended that study continue as planned, to completion​.  Full Article

Vascular Biogenics reports Q2 loss per share $0.18
Monday, 14 Aug 2017 07:00am EDT 

Aug 14 (Reuters) - Vascular Biogenics Ltd :Vbl therapeutics announces second quarter 2017 financial results.Q2 loss per share $0.18.Q2 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.  Full Article

Vascular Biogenics presents positive mid-stage data in brain cancer patients
Monday, 5 Jun 2017 07:30am EDT 

June 5 (Reuters) - Vascular Biogenics Ltd :Vascular biogenics-new data showing treatment with vb-111 induced durable tumor regression,attenuation of tumor growth in patients with recurrent glioblastoma​.Vascular biogenics ltd - ‍first cohort behaved like an avastin historical control with a median overall survival (mos) of 8 months​.Vascular biogenics ltd - ‍second cohort received in median 4 doses of vb-111, about 8 months of treatment​.Vascular biogenics ltd - expects interim analysis of globe trial to occur in q3 2017, with top-line results from full dataset expected in early 2018​.  Full Article

BRIEF-VBL Therapeutics Receives Milestone Payment From Nanocarrier Under Licensing Agreement For VB-111 In Japan

* VBL THERAPEUTICS RECEIVES MILESTONE PAYMENT FROM NANOCARRIER UNDER LICENSING AGREEMENT FOR VB-111 IN JAPAN